MedTrace Logo

A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

NCT06259981 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2025-01-23

No results posted yet for this study

Summary

This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.

Conditions

Interventions

DRUG

GLY-200

2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily

DRUG

Placebo

4 placebo capsules orally twice daily

Sponsors & Collaborators

  • Glyscend, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Fineman, PhD · Glyscend, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2024-10-23
Completion
2024-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06259981 on ClinicalTrials.gov